Nobody rides for free and the avenues you mention will compromise our IP and flexibility.
As CP pointed out the ATM along with the preferred have moved the science well along.
We are getting huge value for our money and proportionate dilution.
It is so against my better judgement to have dialogue with you , moment of weakness.
BTW if you had not noticed prior to "investing" haha, we are a biotech that to this point has never been fully funded. How many loans would have been stacked up to get us to this point.
So we could have exhausted our credit facility, compromised our IP position and still be well short of the goal line. Now what avenues would be available, and what would be the end result dilution beyond recognition and someone else picks up the IP at the fire sale, because we would be riddled with debt.
When Bavi gets approved we will have 325M shares outstanding and the Preferred.
Not bad for a company worth billions.
News 
Market Data 
Discover 
AI
